CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Shenzhen Hepalink Pharma Group Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Shenzhen Hepalink Pharma Group Co Ltd
No. 19
Hi-Tech Zhongyi Avenue
Phone: +86 75526980311p:+86 75526980311 SHENZHEN, GNG  518057  China Ticker: 002399002399
Business Summary
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company focused on the field of heparin sodium preparations and raw materials, macromolecular drugs contract development manufacturing organization (CDMO) and innovative drug development. The Company’s main products and services include enoxaparin sodium preparations and heparin sodium bulk medicines, enoxaparin sodium bulk medicines, and CDMO services for macromolecular drugs. The Company distributes its products within the domestic market and to overseas markets, including Turkey, Brazil, the United States and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board LiLi 59 4/21/1998 1/1/1998
Chief Financial Officer JuanChen 48 8/21/2023 8/21/2023
General Manager, Director YuShan 63 4/21/1998 4/21/1998
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Cytovance Biologics 840 Research Parkway Oklahoma City OK United States

Business Names
Business Name
002399
9989
Cytovance Biologics
Hepalink USA Inc.
Shenzhen Hepalink Pharma. Co., Ltd.

General Information
Number of Employees: 2,080 (As of 12/31/2023)
Outstanding Shares: 1,467,296,204 (As of 12/31/2023)
Shareholders: 26,485
Stock Exchange: SHE
Fax Number: +86 75586142889


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024